Newsfeeds - Spark Newswire

1 minute read

Cowen & Co. Initiates Coverage On Bausch & Lomb with Outperform Rating, Announces Price Target of $35

Today, 10:07 AM

Cowen & Co. analyst Ken Cacciatore initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Outperform rating and announces Price Target of $35.

BLCO

1 minute read

RBC Capital: What To Expect When Bausch Health Companies Reports Q1 Tomorrow

By Vandana Singh

Today, 10:07 AM

RBC Capital Markets expects Bausch Health Companies Inc (NYSE: BHC) Q1 FY22 revenue of $2.02 billion (previous $2.04 billion; consensus $2.05 billion) and adjusted EBITDA of $799 million (previous $816 million; consensus $819 million).

BHC

2 minute read

The Daily Biotech Pulse: Limited Use Of JNJ’s COVID-19 Shot, Myovant-Pfizer’s Relugolix Application Delayed, Gain Therapeutics’ Parkinson’s Data

By Vandana Singh

Today, 10:07 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

AIM

7 minute read

Morning Brief: Top Financial Stories Dominating on Friday, May 6

By Akanksha Bakshi

Today, 10:07 AM

Reuters IHG Hotels & Resorts On Way To Recovery As Travel Booms

AAPL

2 minute read

Bausch + Lomb Corporation Priced 35M Share IPO @$18/Share

By Charles Gross

Today, 10:07 AM

Bausch + Lomb Corporation ("Bausch + Lomb"), a wholly owned subsidiary of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health"), today announced the pricing of its initial public offering ("IPO") of 35,000,000 common shares at a public offering price of $18.00 per share.

BHC

Latest news

Cowen & Co. Initiates Coverage On Bausch & Lomb with Outperform Rating, Announces Price Target of $35

RBC Capital: What To Expect When Bausch Health Companies Reports Q1 Tomorrow

The Daily Biotech Pulse: Limited Use Of JNJ’s COVID-19 Shot, Myovant-Pfizer’s Relugolix Application Delayed, Gain Therapeutics’ Parkinson’s Data

Morning Brief: Top Financial Stories Dominating on Friday, May 6

Bausch + Lomb Corporation Priced 35M Share IPO @$18/Share